This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ecole Polytechnique Federale De Lausanne. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Thomas Gronemeyer: Innovator in AGT Mutants
Introduction: Thomas Gronemeyer, based in Hattingen, Germany, is a notable inventor recognized for his contributions to the field of protein engineering. With one patent to his name, he has developed an innovative approach regarding AGT (O6-alkylguanine-DNA alkyltransferase) mutants with distinct advantages compared to the wild type human AGT.
Latest Patents: Thomas Gronemeyer holds a patent that outlines AGT mutants showcasing two or more advantageous properties. These include enhanced stability, improved solubility, and reduced DNA interactions among others. The mutants are characterized by specific amino acid substitutions and deletions, leading to significant functional improvements in diverse conditions. Moreover, the invention presents a method for detecting or manipulating a protein of interest, incorporating this AGT technology into fusion proteins.
Career Highlights: Gronemeyer is associated with the École Polytechnique Fédérale de Lausanne, where he engages in research that bridges the gap between theoretical studies and real-world applications in protein manipulation. His expertise in biochemistry and molecular biology has led him to explore innovative solutions that advance the understanding of protein interactions and functionalities.
Collaborations: Thomas works alongside distinguished colleagues such as Jan Barnikow and Christopher Chidley, contributing to various projects and enhancing knowledge exchange within the scientific community. Their collaborative efforts reflect a commitment to pushing the boundaries of protein engineering and its applications in biotechnology.
Conclusion: Thomas Gronemeyer's contributions through his patent on AGT mutants signify a substantial advancement in protein engineering. His work not only exemplifies innovation but also highlights the potential for improved therapeutic applications in biotechnology. As a key player in this specialized field, Gronemeyer's research may have far-reaching implications in genetic research and treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile